But now, in a surprise twist, the team that earned the Nobel Prize in chemistry for developing CRISPR is asking to cancel two ...

In recent years, the scientific community has made significant strides in the field of gene editing, particularly through the ...

Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following ...

Two Nobel Prize winners want to cancel their own CRISPR patents in Europe In the decade-long fight to control CRISPR, the ...

CRISPR Therapeutics' stock may seem boring due to slow FDA trial and rollout process, but it's a strong long-term investment.

With the launch of Casgevy gaining momentum, Vertex Pharmaceuticals is adding another link to its gene-editing therapy supply ...

CRISPR Therapeutics' first therapy is called Casgevy. It treats sickle cell disease (SCD) and beta thalassemia, both rare inherited illnesses that affect the function of a person's red blood cells. It ...

Researchers at Weill Cornell Medicine developed a CRISPR-based mouse model to track prostate cancer metastasis. By using ...

Hypothetically, if you controlled which DNA is stored in the CRISPR regions, you could manipulate the bacteria into inserting ...

CRISPR-Cas is used broadly in research and medicine to edit, insert, delete or regulate genes in organisms. TnpB is an ancestor of this well-known 'gene scissor' but is much smaller and thus easier to ...

If you love investing in stocks you're bound to buy some losers. Long term CRISPR Therapeutics AG (NASDAQ:CRSP) shareholders ...

View full profile. Learn about our editorial policies. Like the human immune system, bacteria learn from past infections. CRISPR sequences—short snippets of DNA from previous viruses—guide destructive ...